GlobalRPh Renal Dosing Masterv6.6
Evidence addition

Abiraterone acetate tablets (Yonsa)

Local official-label summaryBase record retrieved 2026-09-05See the evidence for this drug2 sources available - open source summaries, references and comparisons

Yonsa

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Cautions / source differences (1)

Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.

Choose a source to read (2)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

1 additional source qualifications - review before use
A study dose is not this formulation's prescribing dose

The RX renal section cites a study using another abiraterone product.

Before applying: Do not import the other product's study dose as the YONSA regimen.

Also check: A study dose is not this formulation's prescribing dose

Official source

Abiraterone acetate tablets (Yonsa) - selected U.S. label sections

Product / population
YONSA oral tablets only. Do not transfer dosing, food instructions or milligram equivalence from another abiraterone formulation.
Renal measure
Qualitative renal-impairment statement

Selected renal sections only, not a complete monograph. Exact product, indication, patient population, renal method and all other contraindications/interactions remain controlling.

Second independent renal reference and clinician adjudication remain pending; no all-indication, dialysis or pediatric dose may be inferred from an omitted field.

Renal impairment comment

The YONSA label does not require a dose modification for renal impairment. Use the YONSA-specific treatment regimen and accompanying therapy rather than substituting another abiraterone product regimen.

Source revision: Revision not captured; retrieval date is not the revision date. | Retrieved: 2026-09-05. Retrieval date is not the revision date.

Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b8967e10-f768-47ce-ac9e-2324c8390132

Scope: Local label summary; independent clinical review pending. Not a two-source validated protocol. GlobalRPh v6.6.

Full source card / provenance

All sources, comparison tools and evidence navigation
Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Read 1 source difference / applicability notes

Official product label

Abiraterone acetate tablets (Yonsa) - selected U.S. label sections

YONSA oral tablets only. Do not transfer dosing, food instructions or milligram equivalence from another abiraterone formulation.

Renal method: Qualitative renal-impairment statement
Retrieved: 2026-09-05

Read local renal resultOpen original reference
GlobalRPh RX List

GlobalRPh RX List - Yonsa

Pharmacokinetic observation only. Do not convert an exposure finding into an unverified dose.

YONSA formulation. The cited dialysis study used another abiraterone product.

Renal method: ESRD on stable hemodialysis; no new cutoff inferred.
Retrieved: 2026-09-07

Read local renal resultOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. Searches stay on this page and are not saved or sent.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceRead 1 difference / caution notesClinician guide

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Read before choosing a regimen

Source differences and product cautions

Search differences across all drugs

These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.

formulation

A study dose is not this formulation's prescribing dose

The RX renal section cites a study using another abiraterone product.

How to use this: Do not import the other product's study dose as the YONSA regimen.

GlobalRPh RX List - YonsaAbiraterone (ZYTIGA)

Source difference identified; final patient-specific adjudication required.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

New source summary - independent clinical review pending. Summaries of the identified label sections are included locally. Source import and numeric transcription checks are not independent two-reference validation. Do not treat this card as an approved institutional dosing protocol.
Official source

Abiraterone acetate tablets (Yonsa) - selected U.S. label sections

YONSA oral tablets only. Do not transfer dosing, food instructions or milligram equivalence from another abiraterone formulation.

Method: Qualitative renal-impairment statement

Renal impairment commentRead this complete source summary

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopeAbiraterone acetate tablets (Yonsa) - selected U.S. label sectionsGlobalRPh RX List - Yonsa
Choose two source checkboxes below.
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
Locally stored source content

Exact product and population

Product identity selected for the separately displayed source protocols below. Reference: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b8967e10-f768-47ce-ac9e-2324c8390132

Product and population scope

YONSA oral tablets only. Do not transfer dosing, food instructions or milligram equivalence from another abiraterone formulation.

RDM32-abiraterone-yonsa-scope · Source section: Editorial scope for the selected U.S. labelRenal section finder
Separate U.S. product-label layer

FDA / DailyMed dosing and renal information

Official

Abiraterone acetate tablets (Yonsa) - selected U.S. label sections

Open original reference

Open / share this exact local source

U.S. product labeling / DailyMed · YONSA oral tablets only. Do not transfer dosing, food instructions or milligram equivalence from another abiraterone formulation.

Renal method: Qualitative renal-impairment statement
Source date: Revision not captured; retrieval date is not the revision date.
Retrieved: 2026-09-05

Local label summary; independent clinical review pending. Not a two-source validated protocol.

Renal impairment comment

The YONSA label does not require a dose modification for renal impairment. Use the YONSA-specific treatment regimen and accompanying therapy rather than substituting another abiraterone product regimen.

RDM32-abiraterone-yonsa-1 · Source locator: 8.7; 2

Source-specific limits

Selected renal sections only, not a complete monograph. Exact product, indication, patient population, renal method and all other contraindications/interactions remain controlling.

Second independent renal reference and clinician adjudication remain pending; no all-indication, dialysis or pediatric dose may be inferred from an omitted field.

Source identity and provenance
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b8967e10-f768-47ce-ac9e-2324c8390132
Retrieved
2026-09-05
DailyMed Set ID
b8967e10-f768-47ce-ac9e-2324c8390132
Renal-function method
Qualitative renal-impairment statement
Source date/version
Revision not captured; retrieval date is not the revision date.
Hash meaning
SHA-256 identifies this local summary, not original SPL XML or a label PDF.
Local summary SHA-256
43c3190863bb6bcb84ce4176fb471762106ef18d9bb2aa8e9d47036e5f18d53c
Locally imported selected renal sections

GlobalRPh RX List renal information

Rxlist

GlobalRPh RX List - Yonsa

Open original reference

Open / share this exact local source

GlobalRPh-hosted RX List · YONSA formulation. The cited dialysis study used another abiraterone product.

Renal method: ESRD on stable hemodialysis; no new cutoff inferred.
Source date: Revision date not established in selected retrieval.
Retrieved: 2026-09-07

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Pharmacokinetic observation only. Do not convert an exposure finding into an unverified dose.

Locally imported selected source sections; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

The source cites a small pharmacokinetic study in eight patients on stable hemodialysis using a single 1,000 mg dose of another abiraterone product. Exposure did not increase relative to matched controls. That study dose is not the YONSA prescribing dose and must not be substituted for the YONSA-specific regimen.

RDM33-rxlist-abiraterone-yonsa-C1 · Source locator: Clinical pharmacology: patients with renal impairment.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/yonsa-drug/
Retrieved
2026-09-07
Renal-function method
ESRD on stable hemodialysis; no new cutoff inferred.
Source date/version
Revision date not established in selected retrieval.
Hash meaning
SHA-256 of the local authored summary only; original HTML/PDF/SPL bytes are not bundled or hashed.
Local summary SHA-256
0bec679b4fd955914c9faa6e6987feb4a038cb9136f92f52747b7818a0e05d90

Provenance and preservation

Additional summaries stored on this page: 1 official-label, 1 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b8967e10-f768-47ce-ac9e-2324c8390132
Source retrieval
2026-09-05. This is not the source publication or label revision date.
Original source type
multisource addition
Local text SHA-256
ec2b2cc5d9a452420a293aa986276f3d0e554d8f5181dc56af0ae76d09b344b5
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.

Read the full coverage report